Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment.
We report a case of radiation necrosis in an unusual location, the pons, in a patient who had received chemoradiation for nasopharyngeal carcinoma (NPC) over one year prior to presentation. This patient presented with subacute onset of ataxic hemiparesis and slurred speech. Initial magnetic resonance imaging (MRI) studies showed two 1-2 cm peripherally contrast-enhancing lesions in the pons with extensive surrounding edema. Proton magnetic resonance spectroscopy (MRS) played a key role in narrowing the differential diagnosis to radiation necrosis. The patient underwent biweekly bevacizumab therapy and has remained clinically stable with radiologic improvement of his lesion. In addition to this case, we present an overview of the use of advanced neuroimaging in distinguishing radiation necrosis of the central nervous system (CNS) from other entities as well as the role of bevacizumab in treatment.
Harvard Medical School, Boston, MA 02115, USA. matthew_desalvo@hms.harvard.edu
Matthew N
MN
DeSalvo
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D059186:Chemoradiotherapy, Adjuvant; D003937:Diagnosis, Differential; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009336:Necrosis / Q000209:etiology; D011149:Pons / Q000473:pathology* / Q000528:radiation effects; D011832:Radiation Injuries / Q000209:etiology; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
MR spectroscopy; Radiation necrosis; bevacizumab; nasopharyngeal carcinoma; pons